We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

80 hedge funds and large institutions have $314M invested in Cymabay Therapeutics in 2017 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

166% more call options, than puts

Call options by funds: $393K | Put options by funds: $148K

160% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 10

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

28% more capital invested

Capital invested by funds: $244M → $314M (+$69.4M)

25% more funds holding

Funds holding: 64 → 80 (+16)

11% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 18

Holders
80
Holders Change
+16
Holders Change %
+25%
% of All Funds
1.81%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
26
Increased
20
Reduced
18
Closed
10
Calls
$393K
Puts
$148K
Net Calls
+$245K
Net Calls Change
-$31K

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$9.4M
2
UBS AM
UBS AM
Illinois
+$5.04M
3
NC
Nexthera Capital
New York
+$4.46M
4
AAP
Ardsley Advisory Partners
Connecticut
+$3.67M
5
RG
Redmile Group
California
+$3.04M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$14M
2
CAM
Cormorant Asset Management
Massachusetts
-$4.03M
3
A
Abingworth
United Kingdom
-$3.38M
4
Renaissance Technologies
Renaissance Technologies
New York
-$3.21M
5
Deutsche Bank
Deutsche Bank
Germany
-$2.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
76
Prelude Capital Management
New York
$5K -$56.5K -6,610 -93%
CHP
77
Cable Hill Partners
Oregon
$5K +$4.27K +500 New
AIS
78
Accurate Investment Solutions
Pennsylvania
$3K – – –
AG
79
Advisor Group
Arizona
$3K +$2.56K +300 New
CG
80
Cutler Group
California
$3K +$3.42K +400 New
CAM
81
Cormorant Asset Management
Massachusetts
– -$4.03M -500,000 Closed
IHM
82
Iguana Healthcare Management
New York
– -$2.02M -250,000 Closed
BIM
83
Bogle Investment Management
Massachusetts
– -$1.64M -203,580 Closed
CM
84
Crestline Management
Texas
– -$841K -104,392 Closed
SCM
85
Sio Capital Management
New York
– -$605K -75,000 Closed
BFM
86
Boothbay Fund Management
New York
– -$404K -50,077 Closed
Squarepoint
87
Squarepoint
New York
– -$295K -36,570 Closed
SSA
88
Schonfeld Strategic Advisors
New York
– -$278K -34,410 Closed
Tudor Investment Corp
89
Tudor Investment Corp
Connecticut
– -$129K -15,978 Closed
1 2 3
4

CBAY Hedge Fund Activity: Q4 2017 in Review

80 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2017, worth a combined $314M — up 28% from $244M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new CBAY positions and 10 closed out — a net gain of 16 holders — while 20 added to existing stakes and 18 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $9.4M. The largest seller was Millennium Management, cutting an estimated $14M.

  • 80 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2017, up from 64 in Q3 2017.
  • Funds reported $314M of Cymabay Therapeutics stock for Q4 2017, up 28% quarter-over-quarter.
  • 26 funds opened new Cymabay Therapeutics positions in Q4 2017 and 10 closed out, a net change of +16 holders.
  • The largest Cymabay Therapeutics buyer in Q4 2017 was Farallon Capital Management, an estimated $9.4M added.
  • The largest Cymabay Therapeutics seller in Q4 2017 was Millennium Management, an estimated $14M sold.

Based on aggregated 13F filings for Q4 2017.